4045-22-1

Basic information

• Product Name: 1-ACETYLPIPERIDIN-4-OL
• Synonyms: 1-ACETYLPIPERIDIN-4-OL;ETHANONE, 1-(4-HYDROXY-1-PIPERIDINYL)-;OTAVA-BB 1272196;4-piperidinol, 1-acetyl-;1-acetyl-4-piperidinol(SALTDATA: FREE);1-acetyl-4-piperidinol;Ethanone, 1-(4-hydroxy-1-...;1-acetyl-4-hydroxypiperidine
• CAS NO: 4045-22-1
• Molecular Formula: C₇H₁₃NO₂
• Molecular Weight: 143.185
• Mol File: 4045-22-1.mol

Chemical Properties

• Melting Point: 70-73℃
• Boiling Point: 299.369 °C at 760 mmHg
• Flash Point: 134.854 °C
• Appearance: /
• Density: 1.139 g/cm³
• Storage Temp.: 2-8°C
• PKA: 14.47±0.20(Predicted)
• CAS DataBase Reference: 1-ACETYLPIPERIDIN-4-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 1-ACETYLPIPERIDIN-4-OL(4045-22-1)
• EPA Substance Registry System: 1-ACETYLPIPERIDIN-4-OL(4045-22-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 4045-22-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Acetylpiperidin-4-ol is used as a key intermediate in the synthesis of various pharmaceuticals for its potential to contribute to the development of new drugs for the treatment of a wide range of medical conditions.
Used in Chemical Industry:
1-Acetylpiperidin-4-ol is used as a building block in the development of new materials and chemical processes, showcasing its versatility and applicability in advancing chemical research and innovation.

Upstream product

• 5382-16-1 4-HYDROXYPIPERIDINE 
• 60-35-5 acetamide 
• 108-24-7 acetic anhydride 
• 5382-17-2 piperidin-4-ol hydrochloride 
• 32161-06-1 1-acetyl-4-piperidinone 
• 75-36-5 acetyl chloride 
• 178244-37-6 N-acetyl-N-(2-isopropyl-4-oxo-4H-quinazolin-3-yl)acetamide 
• 13880-89-2 3-hydroxyglutaronitrile 

Downstream Products

• 138227-58-4 1-Acetyl-4-(4-nitrophenyloxy)-piperidine 
• 76041-60-6 1-acetyl-4-(2-hydroxy-2-phenylethoxy)piperidine 
• 70978-93-7 4-(2-ethoxyethoxy)piperidine 
• 70978-89-1 4-(2-Phenoxy-ethoxy)-piperidine 
• 110480-68-7 1-acetyl-4-benzhydryloxypiperidine 
• 70978-88-0 4-(1,4-dioxapentyl)piperidine 
• 218922-88-4 7-<<4-(1-acetylpiperidin-4-yloxy)phenyl>(ethoxycarbonyl)methoxy>-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 122368-54-1 4-[(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidine 
• 125602-71-3 [14C]-Bepotastine besilate 
• 125602-71-3 Bepotastine 
• 1560797-69-4 (S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino] butyric acid D-menthyl ester 
• 1560797-78-5 (S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino] butyric acid D-menthyl ester 
• 1560797-70-7 (S)-4-{4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino}butyric acid D-menthyl ester L-tartrate 

Relevant articles and documents

CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS

The present invention provides cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway along with their use in therapeutic applications as described herein.

AZOLE-SUBSTITUTED PYRIDINE COMPOUND

The present invention provides a compound represented by formula [I'| shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme, wherein the structure represented by formula [III] shown below represents any of the structures represented by formula group [IV] shown below, wherein R1 represents a hydrogen atom, a fluorine atom, methyl, etc.; R2, R3, and R4 each independently represent a hydrogen atom, a fluorine atom, or methyl; W represents a single bond, C1-3alkanediyl, or the formula -O-CH2CH2-; and ring A represents (a) substituted C4-6cycloalkyl, (b) substituted 4- to 6-membered saturated nitrogen-containing heterocyclyl, (c) substituted phenyl, (d) substituted pyridyl, (e) substituted 2,3-dihydrobenzofuran, (f) 4- to 6-membered saturated oxygen-containing heterocyclyl, etc.

TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS

A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

Antianemic sideropenic sideropenic syndrome and treatment of the complex compound and for prevention of iron (III)

The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.

Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias

The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.

Anti-inflammatory agents

Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.

METHOD OF SYNTHESIZING BEPOTASTINE OR BENZENESULFONIC ACID SALT THEREOF AND INTERMEDIATES USED THEREIN

The present invention relates to a novel method of synthesizing bepotastine or its benzenesulfonic acid salt and novel intermediates used therein. The present invention uses L-α-hydroxy acid for chiral resolution to form an L-α-hydroxy acid salt of a compound represented by the following formula (VII-1), so as to synthesize bepotastine or its benzenesulfonic acid salt in high optical purity.

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.

KINASE INHIBITORS AND METHODS OF USE

The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.

Piperazine- and piperidine-derivatives as melanocortin receptor agonists

The present invention relates to melanocortin receptor agonists of formula I, which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction.